Analysts

Zealand Pharma (ZEAL) Shares Plunge 23% Following Safety Concerns Over Survodutide Data

06/08/2026, 12:35 PM business stock_drop healthcare
Zealand Pharma's shares fell sharply by 22.7% following concerns over the safety profile of its weight loss drug survodutide, which showed a high dropout rate due to gastrointestinal side effects in a late-stage study. This decline highlights the challenges the company faces in a competitive market dominated by established players like Novo Nordisk and Eli Lilly.
Kontoor Brands

Analysts JPMorgan initiated coverage of Kontoor Brands (KTB) with an overweight rating and a target price of $90, indicating upside potential of over 28%

JPMorgan has initiated coverage of Kontoor Brands with an overweight rating and a price target of $90, suggesting a potential upside of over 28% from its recent closing price. This positive outlook is attributed to the company's focused brand strategy and anticipated revenue growth.